Actionable news
All posts from Actionable news
Actionable news in CLVS: Clovis Oncology, Inc.,

Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%

Clovis Oncology (NASDAQ:CLVS) had a rough day today as shares fell 11% on more than double normal volume. There appears to be a growing lack of confidence that the company's Breakthrough Therapy-tagged lung cancer candidate, rociletinib, will get a "thumbs up" at next week's Ad Comm meeting (Tuesday, April 12). The noise continues to build that the company has been less than forthright with the data from the Phase 3 study so there will be...